Dr Olivia Goff is a Volunteer Writer at BioNews, having originally joined the publication under the auspices of its writing scheme. She obtained a PhD in Neuroscience from University College London's Queen Square Institute of Neurology, where she worked in the laboratory of Professor Dimitri Kullmann, within the Department of Clinical and Experimental Epilepsy. Her research specifically aimed to develop novel gene therapies to treat refractory, focal epilepsy. She previously obtained a BSc in Biochemistry from the University of Bristol. Alongside her research, Olivia is a green representative for her department exploring ways in which the labs can employ more sustainable ways of working.
A Phase 2/3 trial assessing a gene therapy for X-linked retinitis pigmentosa (XLRP) shows significant improvements in low-light vision...
A CRISPR-based therapy continues to reduce harmful cholesterol levels in patients after a one-year follow-up in a Phase 1 clinical trial...
A CRISPR genome editing therapy provides sustained reductions in 'bad' cholesterol in people with inherited high cholesterol or premature coronary artery disease, an early-stage clinical trial shows...
A newly described neurodevelopmental disorder has been linked to changes in a small noncoding gene...
A lipid nanoparticle-based gene therapy for cystic fibrosis restores biological function in a preclinical model...
A topical CRISPR-based genome-editing therapy has been developed to address disease-causing mutations responsible for inherited human skin disorders...
A genome editing therapy robustly reduces harmful cholesterol levels in patients, according to data released from a Phase I clinical trial...
This PET event explored the impact and interplay of three major UK-based genomics and population health research initiatives. This is the first of three in a series of events exploring large-scale biomedical databases and research resources...
The effectiveness of radiotherapy in killing cancer cells depends on the DNA repair pathway the cell uses to fix radiation-induced damage...
The latest PET event, held in partnership with Genomics England, explored how the Generation Study – which involves sequencing the whole genomes of 100,000 newborn babies – is being implemented, and the benefits and risks that may be involved...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
